On January 2, 2018 Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, reported that Marc N. Casper, president and chief executive officer, will present at the 36th Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2018, at 3:00 p.m. (PST) at the Westin St. Francis, San Francisco, Calif (Press release, Thermo Fisher Scientific, JAN 2, 2018, View Source [SID1234522807]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

You can access the live webcast of the presentation in the Investors section of our website, www.thermofisher.com.

On January 2, 2018 Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a company committed to improving patient lives by manufacturing and delivering high quality biologics, reported that its president and chief executive officer, Roger J. Lias, Ph.D., will deliver a corporate presentation at the 10th Annual Biotech Showcase, being held January 8-10, 2018 at the Hilton San Francisco Union Square in San Francisco (Press release, Peregrine Pharmaceuticals, JAN 2, 2018, View Source [SID1234522804]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of this presentation are as follows:

Biotech Showcase 2018
Time/Date: 3:30 p.m. PT on Monday, January 8, 2018
Location: Hilton San Francisco Union Square
Room: Yosemite – B (Ballroom Level)

On January 2, 2018 Genmab A/S (Nasdaq Copenhagen: GEN) reported that its CEO, Jan van de Winkel, Ph.D., will present a company update at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco at 2:00 PM PST on January 10, 2018 (11:00 PM CET) (Press release, Genmab, JAN 2, 2018, View Source [SID1234522803]). A webcast of the presentation will be available on Genmab’s website at View Source

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On January 2, 2018 Celgene Corporation (NASDAQ: CELG) reported that during the 36th Annual J.P. Morgan Healthcare Conference on January 8, 2018 at 10:30 a.m. ET, it will present a business update on the Company in addition to preliminary unaudited 2017 financial results (Press release, Celgene, JAN 2, 2018, View Source [SID1234522802]). The presentation and breakout session can be accessed live by webcast and the financial data will be made available in the Investor Relations section of the Company’s website at www.celgene.com.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On January 2, 2018 ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, reported that Mark Enyedy, President and CEO, will present at the upcoming 36th Annual J.P. Morgan Healthcare Conference in San Francisco. The presentation is scheduled for 8:30am PT (11:30am ET) on January 10, 2018 (Press release, ImmunoGen, JAN 2, 2018, View Source [SID1234522798]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Following the presentation, Mr. Enyedy will be joined by other members of ImmunoGen’s management team for a question-and-answer session at 9:00am PT (12:00pm ET).

A webcast of the presentation and question-and-answer session will be accessible live through the "Investors" section of the Company’s website, www.immunogen.com; a replay will be available in the same location for approximately two weeks.